The CFO of Harvard Bioscience in Holliston is set to step down from her role after a three-year stint with the company. Harvard Bioscience CFO and Treasurer Jennifer Cote will resign from her role ...

Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial FlexibilityBroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board on ...

Fintel reports that on April 9, 2025, Keybanc downgraded their outlook for Harvard Bioscience (NasdaqGM:HBIO) from Overweight to Sector Weight. Analyst Price Forecast Suggests 944.80% Upside As of ...

Holliston biotechnology firm Harvard Bioscience continued its fourth quarter momentum with revenue up 14% in the first quarter of 2021 when compared to the first quarter of 2020. Holliston ...

Harvard Bioscience's Q2 earnings showed a slight miss on EPS and revenue, causing a decline in the stock price. The company is committed to improving its product portfolio and has observed increased ...

HOLLISTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Jennifer Cote, the Company’s Chief Financial Officer and ...

Harvard Bioscience, Inc. will release its financial results for the fourth quarter of 2024 on March 12, 2025, before the market opens, and will host a conference call at 8:00 a.m. Eastern Time to ...

Harvard Bioscience, Inc. (Nasdaq: HBIO) will release its financial results for the first quarter of 2025 on May 12, 2025, before the market opens, followed by a conference call at 8:00 a.m. Eastern ...

Harvard Bioscience (HBIO) entered into an agreement with BroadOak Capital Partners to provide a $40M credit facility comprised of three term ...

The MarketWatch News Department was not involved in the creation of this content. HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or ...

Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board members Q2 ’25 revenue anticipated to be $20.4 million and Company reiterates ...

Harvard Bioscience's shares are up more than 105% so far this year. The company is seeing strong sales from its equipment to aid in CRISPR gene-editing. Harvard Bioscience also saw improved net income ...